H
Howard A. Burris
Researcher at Sarah Cannon Research Institute
Publications - 593
Citations - 40779
Howard A. Burris is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 80, co-authored 568 publications receiving 34783 citations. Previous affiliations of Howard A. Burris include American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
Recent updates on the role of chemotherapy in pancreatic cancer.
TL;DR: Promising results in a phase II trial of gemcitabine in combination with bevacizumab have led to a randomized comparative trial of the combination.
Journal ArticleDOI
Prevention of Docetaxel-Induced Erythrodysesthesia With Local Hypothermia
Greta C. Zimmerman,James H. Keeling,Mary Lowry,Jerry Medina,Daniel D. Von Hoff,Howard A. Burris +5 more
Journal ArticleDOI
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
Sunil Sharma,Elisabeth G.E. de Vries,Jeffrey R. Infante,Corina N.A.M. Oldenhuis,Jourik A. Gietema,Lin Yang,Sanela Bilic,Katie Parker,Michael Goldbrunner,Jeffrey W. Scott,Howard A. Burris +10 more
TL;DR: LBY135 was well tolerated up to 40 mg/kg, the maximal dose administered; no MTD for LBY135 ± capecitabine was defined.
Journal ArticleDOI
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Edith A. Perez,Sanne de Haas,Wolfgang Eiermann,Carlos H. Barrios,Masakazu Toi,Young Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Sven Stanzel,Monika Patre,Paul Anthony Ellis +13 more
TL;DR: In MARIANNE, biomarkers related to the HER2 pathway did not have predictive value for PFS when comparing T-DM1 (with or without pertuzumab) with trastuzuab plus taxane, however, HER2 mRNA level and PIK3CA mutation status showed prognostic value.
Journal ArticleDOI
Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Dan Lu,Howard A. Burris,Bei Wang,E. Claire Dees,Javier Cortes,Amita Joshi,Manish Gupta,Joo-Hee Yi,Yu-Waye Chu,Ted Shih,Liang Fang,Sandhya Girish +11 more
TL;DR: The results show that the exposure of T-DM1 and DM1 was comparable with that reported by historical single-agent studies in patients with HER2-positive MBC, and the risk of TP-DI appears to be low when T- DM1 and pertuzumab are given together.